Cumulative incidence and determinants of carbapenem-resistant Enterobacterales clearance in hospitalized patients: a competing-risks analysis addressing surveillance-time, immortal-time, and ascertainment bias
This study utilizes competing-risks analysis to demonstrate that approximately 38% of hospitalized patients with carbapenem-resistant Enterobacterales achieve clearance by day 90, with significantly higher rates among carbapenemase-negative carriers, while revealing that previously identified predictors of clearance may be artifacts of surveillance and ascertainment biases.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Hospitals are places where the sick go to heal, but they are also places where dangerous germs can hide and spread. Among the most formidable of these are bacteria known as carbapenem-resistant Enterobacterales, or CRE. These are tough microbes that have learned to survive the strongest antibiotics doctors have, making infections caused by them difficult to treat and often deadly. Because these bacteria can live inside a person without making them sick—just quietly colonizing the gut—hospitals must take strict measures to stop them from jumping to other patients. This usually means isolating the carrier in a single room and requiring staff to wear gowns and gloves. However, these precautions are heavy on resources and can make patients feel cut off from the care they need. The critical question for infection control teams is simple but hard to answer: when is it safe to stop these precautions? When can a patient be declared free of the bacteria and allowed to mix with others again?
For years, doctors have tried to figure out how long these bacteria stick around and what factors help a person clear them. But answering this question is surprisingly tricky. To know if a patient is clear, doctors must take repeated tests over time. If a patient leaves the hospital or dies before enough tests are done, they might be wrongly counted as still carrying the bacteria, or their data might be ignored entirely. Furthermore, if a patient has to survive for a long time just to get the tests done that prove they are clear, comparing them to those who died early creates a misleading picture of who is safer. These hidden pitfalls in how data is collected and analyzed have made it difficult to know the true timeline of recovery or to predict which patients will clear the infection faster.
A team of researchers at Kangbuk Samsung Hospital in Seoul, South Korea, decided to tackle these problems head-on. They looked back at the records of 428 adults who were found to carry CRE between 2020 and 2023. Instead of using standard methods that might miss the subtle ways patients drop out of the study or die, the researchers used a more rigorous approach designed to account for these realities. They treated death as a competing event, meaning they acknowledged that if a patient died, they could no longer clear the bacteria, and this fact had to be counted in the final numbers. They also carefully checked their methods to ensure that the time a patient spent alive and being tested didn't artificially make it look like clearing the bacteria helped them survive.
The results revealed a clearer picture of how these bacteria behave. By the 90th day after detection, roughly two out of every five patients had successfully cleared the bacteria from their system. However, this success was not evenly distributed. The researchers found a major difference based on the specific genetic makeup of the bacteria. Patients carrying bacteria that did not produce a specific enzyme called a carbapenemase were much more likely to clear the infection. By day 60, more than half of the patients with these non-enzyme bacteria had cleared them, compared to only about one in six of the patients carrying the enzyme-producing version. This suggests that the type of bacteria matters far more than the patient's age or other health conditions when it comes to getting rid of the infection.
The study also challenged some common assumptions about what helps a patient recover. In earlier, less careful analyses, factors like having a solid tumor appeared to be linked to clearing the bacteria. However, when the researchers adjusted their methods to remove the bias caused by how and when patients were tested, these links disappeared. It turned out that patients with solid tumors were simply more likely to be tested frequently after leaving the hospital, which made it look like they cleared the bacteria more often. In reality, the data showed that no single patient characteristic reliably predicted who would clear the infection. The only thing that was clear was the type of bacteria itself.
Perhaps the most striking finding concerned the safety of the patients. The researchers looked at whether clearing the bacteria helped patients survive. They found that no patient died after they had successfully cleared the infection. While this sounds like good news, the researchers explained that it is actually a statistical illusion. Because a patient must survive long enough to get the tests that prove they are clear, they are already a survivor by the time they are counted as "cleared." Comparing them to those who died earlier creates a false sense that clearing the bacteria saves lives. When the researchers corrected for this, they found that the real threats to survival were things like having a central line for medicine or being on a breathing machine, not whether the bacteria was still present.
This work suggests that the rules for stopping isolation in hospitals should be based on the type of bacteria a patient carries rather than a checklist of the patient's other health problems. For those carrying the enzyme-producing bacteria, the odds of clearing the infection quickly are low, and precautions may need to stay in place longer. For those without the enzyme, the chances of clearing it are much higher. By using methods that account for the realities of hospital stays and patient survival, the researchers provided a more honest map of how these infections resolve. Their findings remind us that in the fight against superbugs, the way we measure success is just as important as the success itself, and that careful counting can reveal truths that simple observation might miss.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.